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Selective hepatitis B and D virus 
entry inhibitors from the group 
of pentacyclic lupane‑type 
betulin‑derived triterpenoids
Michael Kirstgen1, Kira Alessandra Alicia Theresa Lowjaga1, Simon Franz Müller1, 
Nora Goldmann2, Felix Lehmann2, Sami Alakurtti3,4, Jari Yli‑Kauhaluoma3, Dieter Glebe2 & 
Joachim Geyer1*
Current treatment options against hepatitis B and D virus (HBV/HDV) infections have only limited 
curative effects. Identification of  Na+/taurocholate co‑transporting polypeptide (NTCP) as the high‑
affinity hepatic receptor for both viruses in 2012 enables target‑based development of HBV/HDV 
cell‑entry inhibitors. Many studies already identified appropriate NTCP inhibitors. However, most of 
them interfere with NTCP’s physiological function as a hepatic bile acid transporter. To overcome this 
drawback, the present study aimed to find compounds that specifically block HBV/HDV binding to 
NTCP without affecting its transporter function. A novel assay was conceptualized to screen for both 
in parallel; virus binding to NTCP (measured via binding of a preS1‑derived peptide of the large HBV/
HDV envelope protein) and bile acid transport via NTCP. Hits were subsequently validated by in vitro 
HDV infection studies using NTCP‑HepG2 cells. Derivatives of the birch‑derived pentacyclic lupane‑
type triterpenoid betulin revealed clear NTCP inhibitory potency and selectivity for the virus receptor 
function of NTCP. Best performing compounds in both aspects were 2, 6, 19, and 25. In conclusion, 
betulin derivatives show clear structure–activity relationships for potent and selective inhibition of 
the HBV/HDV virus receptor function of NTCP without tackling its physiological bile acid transport 
function and therefore are promising drug candidates.
Infections with the Hepatitis B (HBV) and D (HDV) viruses are the main cause of hepatocellular carcinoma 
(HCC) and liver cirrhosis as consequences of chronic hepatitis. Although vaccination is possible, more than 250 
million people worldwide suffer from chronic hepatitis based on HBV/HDV infections, and 887,000 deaths can 
be traced back to this every  year1. The genome of the enveloped DNA virus HBV consists of 3.2 kb which encode 
for three envelope proteins, referred to as small (SHBs), middle (MHBs), and large (LHBs)2. The 2–48 N-terminal 
amino acids of the myristoylated preS1 domain (myr-preS12-48 lipopeptide) of the LHBs are essential for virus 
binding to  hepatocytes3,4. As HDV is a satellite virus of HBV and bears identical envelope proteins, it also shares 
this myr-preS12-48  lipopeptide5. About 5% of all chronic HBV carriers are additionally infected with  HDV1. 
This co-infection causes more rapid disease progression, increased mortality rates, and increased incidence of 
HCC and liver  cirrhosis6. To date, there are only few treatment options for HBV and HDV infections available. 
Chronic hepatitis can usually be controlled by antiviral therapy with nucleoside reverse transcriptase inhibitors 
and interferon. This is, however, rarely curative. Furthermore, interferon therapy is highly prone to adverse drug 
reactions and nucleoside reverse transcriptase inhibitors have to be given life-long7,8.
A promising novel drug target to block HBV/HDV virus entry into hepatocytes is represented by the  Na+/
taurocholate co-transporting polypeptide NTCP (gene symbol SLC10A1), which has been identified as the bona 
fide hepatic receptor for HBV/HDV9,10. It is generally accepted that HBV/HDV entry into hepatocytes essentially 
involves attachment of the virus particles to heparan sulfate  proteoglycans11, followed by high-affinity binding of 
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the myr-preS1 domain of the large envelope protein to certain domains of NTCP that finally triggers subsequent 
steps such as endocytosis of the virus-receptor  complex12.
It is known for long that an artificial myr-preS12-48 lipopeptide itself can block in vitro HBV/HDV infection in 
a dose-dependent manner with inhibitory constants  (IC50) in the low nanomolar  range4. Based on this, a synthetic 
analogue of the myr-preS12-48 lipopeptide, called bulevirtide (generic name, formerly known as Myrcludex B), was 
developed as a therapeutic agent against HBV and HDV infections. Several clinical studies have been successfully 
completed and very recently, bulevirtide was approved as a new drug to treat hepatitis D in Europe and Russia 
and will be marketed under the brand name  Hepcludex13. Furthermore, it was demonstrated that viral DNA 
(HBV) and RNA (HDV) levels can be reduced significantly in chronically infected patients with a combination 
of bulevirtide and pegylated interferon alpha (PEG-IFNα)14. These data clearly indicate that NTCP is an appro-
priate drug target to control hepatic HBV/HDV levels. In addition, an HBV/HDV entry inhibitor addressing 
NTCP might be beneficial to prevent new infections of hepatocytes during chronic infection with HBV/HDV12.
Physiologically, NTCP is expressed dominantly at the basolateral membrane of hepatocytes and acts as a 
sodium-dependent uptake carrier of bile salts to enable their enterohepatic  recirculation15–17. Thus, NTCP has 
a dual function as bile salt transporter and virus receptor. It is already known that both functions interfere with 
each other. The myr-preS12-48 lipopeptide can block the bile salt transport in primary human hepatocytes and 
NTCP-overexpressing HepG2 hepatoma cells in a concentration-dependent manner. Vice versa, bile salts can 
prevent myr-preS12-48 lipopeptide binding to NTCP as well as in vitro HBV  infection10,18. Based on this, it was 
expected that in clinical trials using bulevirtide as a therapeutic agent, the total plasma bile salt levels would 
increase significantly. In a current study on healthy volunteers who received 10 mg bulevirtide, which is above 
the therapeutic dose, total plasma bile salt levels indeed increased 19.2-fold, and single bile salts even higher (e.g. 
124-fold in the case of taurocholic acid, further referred to as TC)19. This data can be interpreted as dysregulation 
of the bile acid homeostasis under bulevirtide treatment.
On the basis of the therapeutically used effects of bulevirtide, a promising second strategy for the develop-
ment of HBV/HDV entry inhibitors targeting NTCP would be to (I) investigate small molecules with oral bio-
availability which (II) block virus binding to NTCP, but (III) without tackling its physiologically important bile 
salt transporter activity at relevant therapeutic drug concentrations. Currently, several studies identified novel 
chemical entry inhibitors for HBV and HDV by screening for bile salt transport  inhibitors20 or by screening 
for inhibitors of myr-preS12-48 lipopeptide attachment and/or in vitro HBV/HDV  infection21 in appropriate cell 
culture models overexpressing NTCP. However, none of these studies addressed and fulfilled all of the criteria 
outlined above. In contrast, the present study aimed to find small molecular HBV/HDV entry inhibitors that 
specifically block myr-preS12-48 lipopeptide binding to NTCP without affecting its bile salt transport function. 
We analyzed a set of derivatives of the pentacyclic lupane-type triterpenoid betulin, and indeed found individual 
compounds that were quite potent and selective for myr-preS12-48 lipopeptide binding inhibition and signifi-
cantly blocked in vitro HDV infection of NTCP-expressing HepG2 cells. These compounds now can be further 
optimized for increased potency and then can be forwarded for in vivo infection experiments.
Results
Screening assay for bile acid transport and myr‑preS12‑48 lipopeptide binding. The major goal 
of the present study was to analyze in parallel the effect of inhibitors on both, bile acid transport via NTCP and 
myr-preS12-48 lipopeptide binding to NTCP in a cell culture system. This was achieved by plating NTCP-HEK293 
cells onto 96-well plates and by using tritium-labelled analytes, being  [3H]taurocholic acid  ([3H]TC) and  [3H]
myr-preS12-48 lipopeptide  ([3H]preS1), which were analyzed in a microplate scintillation counter. For validation 
of this assay, transport of 1 µM  [3H]TC first was inhibited by increasing concentrations of TC (concentrations 
ranging from 0.1 to 1,000 µM) itself and by myr-preS12-48 lipopeptide (concentrations ranging from 0.001 to 
10 µM). In addition, binding of 5 nM  [3H]preS1 was inhibited by myr-preS12-48 lipopeptide itself (concentrations 
ranging from 0.001 to 10 µM) and by TC (concentrations ranging from 0.1 to 1,000 µM). As shown in Fig. 1a, 
TC showed nearly equipotent inhibition of the  [3H]TC transport with  IC50 of 30 µM and of the  [3H]preS1 bind-
ing with  IC50 of 42 µM. The same was true for myr-preS12-48 lipopeptide as the inhibitor that revealed  IC50 of 
0.35 µM for  [3H]TC transport inhibition and  IC50 of 0.55 µM for  [3H]preS1 binding inhibition (Fig. 1b). These 
data clearly confirm the previously shown interference of the transport and receptor function of  NTCP10,18 and 
demonstrate the functionality of this screening assay. Furthermore, these data indicate that the myr-preS12-48 
lipopeptide has an about 100-fold higher inhibitory potency  (IC50 = 0.35 µM / 0.55 µM) in both assays compared 
to the physiological transport substrate TC  (IC50 = 30 µM / 42 µM). Four reference compounds were analyzed 
(concentrations ranging from 0.1 to 1,000 µM) which had shown inhibition of the transporter and receptor 
function of NTCP before, namely  ciglitazone22,  troglitazone22, cyclosporine  A23–25, and  rapamycin26. Interest-
ingly, all compounds showed comparable inhibition of  [3H]TC uptake and  [3H]preS1 binding with  IC50 values 
of 1 µM and 1.3 µM for ciglitazone (Fig. 1c), 1.9 µM and 2.5 µM for troglitazone (Fig. 1d), 14 µM and 26 µM for 
cyclosporine A (Fig. 1e), as well as 34 µM and 21 µM for rapamycin (Fig. 1f), respectively. These compounds 
therefore can be classified as inhibitors, non-selective for one of the two measured functions of NTCP. Among 
them, ciglitazone and troglitazone had a tenfold higher inhibitory potency compared to cyclosporine A and 
rapamycin, demonstrating that diverse compounds differ in their potency as NTCP inhibitors. Cyclosporine A, 
rapamycin and TC showed comparable inhibitory pattern and potency in both assays, as shown by similar  IC50 
values.
Screening of betulin derivatives for bile acid transport and  [3H]preS1 binding inhibition. Next, 
30 derivatives of betulin were tested in both assays and  IC50 values were determined for  [3H]TC transport inhibi-
tion and  [3H]preS1 binding inhibition. Chemical structures of all compounds are depicted in Table 1. All derive 
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Figure 1.  [3H]TC transport and  [3H]preS1 binding screening assay. NTCP-HEK293 cells were seeded onto 96-well 
plates and were incubated with tetracycline in order to induce expression of the human NTCP protein. Cells without 
tetracycline treatment were used as 0% controls of  [3H]TC uptake and  [3H]preS1 binding, respectively. Cells were 
subjected to bile acid transport experiments with 1 µM  [3H]TC and myr-preS12-48 lipopeptide binding experiments with 
5 nM  [3H]preS1, each over 10 min at 37 °C. Experiments were performed with solvent alone (set to 100%) and with 
increasing concentrations of the indicated inhibitors. The mean of the 0% control was subtracted to calculate net  [3H]TC 
transport rates (shown in blue) as well as net  [3H]preS1 binding rates (shown in red), which are depicted in the diagrams 
(expressed as % of control at the y-axis). Half maximal inhibitory concentrations  (IC50) were calculated by nonlinear 
regression analysis using the equation log(inhibitor) versus response (GraphPad Prism). In order to validate the assay, (a) 
TC and (b) myr-preS12-48 lipopeptide were used as inhibitors. Furthermore, the already established NTCP inhibitors (c) 
ciglitazone, (d) troglitazone, (e) cyclosporine A, and (f) rapamycin were analyzed for  [3H]TC transport inhibition and 
 [3H]preS1 binding inhibition. Data represent means ± SD of quadruplicate determinations of representative experiments.
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Table 1.  Structures of the betulin derivatives that were used for  [3H]TC transport inhibition and  [3H]preS1 
binding inhibition experiments. These compounds derived from a TargoSet (Adipogen AG) or were synthesized 
as outlined  elsewhere52–54. Ac, acetyl; Asp, aspartate; Et, ethyl; Me, methyl; Ph, phenyl; Pyr, pyridinyl; THP, 
2H-tetrahydropyranyl.
No Compound R1 R2 R3
1 Betulin OH CH2OH CH3-C=CH2
2 20,29-Dihydrobetulin OH CH2OH CH3-CH-CH3
3 Lupeol OH Me CH3-C=CH2
4 Betulinic acid OH CO2H CH3-C=CH2
5 Methyl betulinate OH CO2Me CH3-C=CH2
6 Betulinaldehyde oxime OH CH=NOH CH3-C=CH2
7 OH CH2O2CCH2Br CH3-C=CH2
8 28-O -Succinoylbetulin OH CH2O2C(CH2)2CO2H CH3-C=CH2
9 3,28-Di-O -succinoylbetulin O2C(CH2)2CO2H CH2O2C(CH2)2CO2H CH3-C=CH2
10 28-O -(3,3-Dimethylglutaroyl)betulin OH CH2O2C(CH2)CMe2(CH2)CO2H CH3-C=CH2
11 3-O -(3,3-Dimethylglutaroyl)betulinic acid O2C(CH2)CMe2(CH2)CO2H CO2H CH3-C=CH2
12 3,28-Di-O -(3,3-dimethylglutaroyl)betulin O2C(CH2)CMe2(CH2)CO2H CH2O2C(CH2)CMe2(CH2)CO2H CH3-C=CH2
13 28-(Tetrahydro-2H -pyran-2-yl)betulin OH CH2O(THP) CH3-C=CH2
14 28-O -Niconoylbetulin OH CH2O2C(3-Pyr) CH3-C=CH2
15 28-O -Cinnamoylbetulin OH CH2O2C(CH=CH)Ph-(E ) CH3-C=CH2
16 3,28-Di-O -(dihydrocinnamoyl)betulin O2C(CH2)2Ph CH2O2C(CH2)2Ph CH3-C=CH2
17 Lupenone O= Me CH3-C=CH2
18 Betulonaldehyde O= CHO CH3-C=CH2
19 Betulonoyl dimethyl-L-aspartate O= CO[Asp(OMe)-OMe] CH3-C=CH2
20 20,29-Dihydrobetulonic acid O= CO2H CH3-CH-CH3
21 3-O -Acetylbetulinic acid OAc CO2H CH3-C=CH2
22 3-O -Acetylbetulin OAc CH2OH CH3-C=CH2
23 3-O -Acetyl-28-(tetrahydro-2H -pyran-2-
yl)betulin
OAc CH2O(THP) CH3-C=CH2
24 3,28-Di-O -acetylbetulin OAc OAc CH3-C=CH2
25 3,28-Di-O -acetyl-29-hydroxybetulin OAc OAc HOCH2-C=CH2
26 3,28-Di-O -acetyl-20,30-epoxybetulin OAc OAc
27 3-O -Caffeoylbetulin O2C(CH=CH)(3,4-di-OH-C6H3)-(E ) CH2OH CH3-C=CH2
28 3,28-Di-O -acetyl-18,19-dehydro-20,29-
dihydrobetulin
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from the betulin core structure by chemical modifications. These include methyl, succinyl, acetyl, bromoacetyl, 
dimethylglutaryl, caffeoyl, oxime, tetrahydropyranyl, cinnamoyl, nicotinoyl, L-aspartyl- or 1,2,4-triazoline-
3,5-dione conjugations mostly at positions 3′ and/or 28′, as well as oxidations of the hydroxyl groups at posi-
tions 3′ and/or 28′. Compound 29 represents allobetulin and compound 30 3-oxoallobetulin. All  IC50 values for 
 [3H]TC transport and  [3H]preS1 binding are listed in Table 2 with their 95% confidence intervals, and selected 
diagrams are shown in Fig. 2. In the case of  [3H]TC uptake inhibition, the  IC50 values ranged from 1 µM (4) 
up to values > 1,000 µM with very low, if any transport inhibition (3, 24, 25, 28 and 30). This clearly indicates 
structure–activity relationships over three orders of magnitude. Most of the betulin derivatives showed quite 
potent inhibition of  [3H]preS1 binding with  IC50 values ranging from 2–3 µM (4, 8, 21) up to 199 µM (24), also 
demonstrating clear structure–activity relationships over a broad inhibitor concentration range.  
In addition, ratios between the  IC50 values for  [3H]TC transport inhibition and the  IC50 values for  [3H]preS1 
binding inhibition were calculated and are further referred to as selectivity index. The higher this index, the 
more selective the respective compound for myr-preS12-48 lipopeptide inhibition. Therefore, the data listed in 
Table 2 are not only helpful to identify potent myr-preS12-48 lipopeptide binding inhibitors but also to assess 
their selectivity. These values ranged from an index of 1, including more potent (e.g. 4) and less potent (e.g. 12) 
non-selective inhibitors, up to an index of > 60, including the highly selective and potent inhibitors 2 and 25. 
Figure 2 depicts selected diagrams which show the inhibitory curves for the  [3H]TC transport inhibition (in 
blue) and  [3H]preS1 binding inhibition (in red). This panel shows compounds with different characteristics. 
Within the group of potent  [3H]preS1 binding inhibitors  (IC50 < 10 µM), there were (I) non-selective inhibitors 
Table 2.  The indicated 31 betulin derivatives were analyzed for  [3H]TC transport inhibition and  [3H]
preS1 binding inhibition in NTCP-HEK293 cells.  IC50 values were calculated from a range of five inhibitor 
concentrations (0.1–1,000 µM) and are listed with their 95% confidence intervals. Selectivity indices for  [3H]
TC transport inhibition/[3H]preS1 binding inhibition were calculated from the  IC50 means. The higher this 
index, the more selective the respective inhibitor. a Inhibition of 1 µM  [3H]TC uptake; b inhibition of 5 nM 
 [3H]preS1 binding; c calculated from mean  IC50 TC:preS1.
Compound IC50  ([3H]TC uptake) [µM]a IC50  ([3H]preS1 binding) [µM]b Selectivity  indexc
Betulinic acid (4) 0.65–1.08 1.57–2.93 1
20,29-Dihydrobetulonic acid (20) 2.74–5.46 2.95–7.66 1
3,28-Di-O-succinoylbetulin (9) 3.11–5.02 2.94–10.15 1
28-O-(3,3-Dimethylglutaroyl)betulin (10) 3.00–5.91 2.48–7.02 1
3-O-(3,3-Dimethylglutaroyl)betulinic acid (11) 3.08–4.53 3.00–5.21 1
3,28-Di-O-(3,3-dimethylglutaroyl)betulin (12) 4.17–10.71 4.97–10.14 1
3-O-Acetylbetulin (22) 36.47–151.80 20.64–87.35 2
Methyl betulinate (5) 47.05–99.97 12.66–83.46 2
28-O-Succinoylbetulin (8) 5.35–10.60 1.61–4.11 3
Betulonaldehyde (18) 88.53–175.00 25.98–52.00 3
28-O-Nicotinoylbetulin (14) 185.40–531.50 36.48–109.10 5
3-O-Acetylbetulinic acid (21) 7.19–30.33 1.81–5.31 5
3,28-Di-O-acetylbetulin (24)  > 1,000 52.55–756.00  > 5
3,28-Di-O-(dihydrocinnamoyl)betulin (16) 176.20–1232.00 24.79–229.20 6
4′-Ethyl-1′,2′,4′-triazoline-3′,5′-dione-fused 
3,28-di-O-acetylbetulin (31) 614.20–1286.00 89.71–224.60 6
Betulin (1) 568.80–983.40 48.29–247.10 7
28-O-Cinnamoylbetulin (15) 72.39–235.50 10.89–31.75 7
3-O-Acetyl-28-(tetrahydro-2H-pyran-2-yl)betulin 
(23) 119.00–947.20 10.95–113.70 10
Lupenone (17) 145.70–396.70 13.10–35.45 11
28-O-(Bromoacetyl)betulin (7) 63.53–126.00 5.28–11.14 11
3,28-Di-O-acetyl-20,30-epoxybetulin (26) 331.80–891.20 26.46–72.96 12
3,28-Di-O-acetyl-18,19-dehydro-20,29-dihydrobet-
ulin (28)  > 1,000 29.95–132.80  > 16
Lupeol (3)  > 1,000 26.93–97.94  > 19
28-(Tetrahydro-2H-pyran-2-yl)betulin (13) 115.80–628.00 9.34–19.54 19
3-O-Caffeoylbetulin (27) 84.98–195.00 3.35–10.00 22
Allobetulin (29) 212.30–674.80 9.67–20.80 27
Betulonoyl dimethyl-L-aspartate (19) 297.60–1430.00 21.84–202.60 28
3-Oxoallobetulin (30)  > 1,000 17.87–54.43  > 32
Betulinaldehyde oxime (6) 359.80–759.00 6.61–18.29 48
20,29-Dihydrobetulin (2) 157.80–428.90 1.74–7.14 65
3,28-Di-O-acetyl-29-hydroxybetulin (25)  > 1,000 5.29–13.04  > 125
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Figure 2.  Inhibition of  [3H]preS1 peptide binding and  [3H]TC transport by betulin derivatives. NTCP-HEK293 cells were incubated 
with tetracycline in order to induce NTCP expression and were used for bile acid transport experiments with 1 µM  [3H]TC and for 
myr-preS12-48 lipopeptide binding experiments with 5 nM  [3H]preS1, each over 10 min at 37 °C. Cells without tetracycline treatment 
were used as 0% controls of  [3H]TC uptake and  [3H]preS1 binding, respectively. Experiments were performed with solvent alone (set 
to 100%) and with increasing concentrations of the indicated inhibitor. The mean of the 0% control was subtracted to calculate net  
[3H]TC transport rates (shown in blue) as well as net  [3H]preS1 binding rates (shown in red), both expressed as % of control at 
the y-axis. Half maximal inhibitory concentrations  (IC50) were calculated by nonlinear regression analysis using the equation 
log(inhibitor) vs. response (GraphPad Prism). The figure shows selected diagrams. Chemical structures of the compounds are depicted 
in Table 1, the respective  IC50 values are listed in Table 2. Data represent means ± SD of quadruplicate determinations (n = 4).
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(4, 9, 10, and 20), (II) poorly selective inhibitors (e.g. 21), and highly selective inhibitors, being 2 and 25. Also, 
from the group of less potent  [3H]preS1 binding inhibitors  (IC50 = 11–50 µM), some were poorly selective (e.g. 
18) and others were highly selective (e.g. 13, 17, 19 and 30). Taken together, these data clearly indicate struc-
ture–activity relationships of the betulin derivatives for both, bile acid transport inhibition and myr-preS12-48 
lipopeptide binding inhibition.
Most relevant modifications for structure–activity relationships. Closer analysis of the struc-
ture–activity relationships of the betulin derivatives revealed several interesting patterns that can be used to 
further optimize the potency and selectivity index of these compounds in order to end up with an even more 
suitable HBV/HDV entry inhibitor from the class of betulin derivatives. Of note, betulin (1) itself showed rela-
tively low inhibitory potency for bile acid transport inhibition  (IC50 = 748 µM) and  [3H]preS1 binding inhibition 
 (IC50 = 109 µM) resulting in a selectivity index of 7. However, relatively moderate modifications at the betulin 
core structure revealed significantly improved potency and selectivity index of the individual compounds. Some 
of these modifications are depicted in more detail in Fig. 3a/3b and involve modifications at positions 3′, 28′, 29′, 
and 30′. While the diacetylated betulin derivative 3,28-di-O-acetylbetulin (24) itself has a relatively low potency 
for  [3H]preS1 binding inhibition  (IC50 = 199 µM) and poor selectivity (selectivity index: 5) (Fig. 3, shown in 
orange), additional  C29 hydroxylation (25) improved the potency for  [3H]preS1 binding inhibition to  IC50 = 8 µM 
and increased the selectivity index to 125 (Fig. 3, shown in purple). 3-O-caffeoyl (27) conjugation of betulin (1) 
also reduced the  IC50 value for  [3H]preS1 binding inhibition to 6 µM and increased the selectivity index to 22 
(Fig. 3, shown in light blue). Replacement of the 28-hydroxyl group of betulin by an oxime group (6) increased 
the inhibitory potency for  [3H]preS1 binding by one order of magnitude (109 µM vs. 11 µM) and also improved 
the selectivity index (7 vs. 48) (Fig. 3, shown in red). The most successful modification, however, was the satura-
tion of the double bond between  C20 and  C30, which increased the potency for  [3H]preS1 binding inhibition to 
 IC50 of 4 µM, while maintaining the low degree of interference with the bile acid transport with  IC50 of 260 µM 
(selectivity index: 65) (Fig. 3, shown in green).
Acidic betulin derivatives are potent, but non‑selective inhibitors of NTCP. All potent  (IC50 
preS1 binding < 10 µM) and non-selective (selectivity index < 10) NTCP inhibitors from the group of betulin 
derivatives bear at least one acidic group. This applies to compounds 4, 8—12, 20, and 21 (Tab. 1). Based on their 
pKa values, these compounds are predominantly deprotonated and negatively charged at pH 7.4, similar to bile 
acids. In order to investigate the role of the pH-dependent negative charge of these compounds, the acidic deriv-
atives 4 (pKa = 4.8) and 8 (pKa = 4.1) were tested for  [3H]TC uptake inhibition and  [3H]preS1 binding inhibition 
at pH 7.4 and pH 5.5. Betulin (1) was included as a non-acidic compound for control. In the case of compound 
4 a shift of the  IC50 value for  [3H]TC uptake inhibition from 0.8 to 103 µM was observed (Fig. 4, upper panel). 
Compound 8 also showed an  IC50 shift from 8 to 200 µM by lowering the pH from 7.4 to 5.5. Interestingly, the 
 IC50 values for  [3H]preS1 binding inhibition did not change at lower pH (Fig. 4, lower panel). Apart from this 
effect on the inhibition pattern, acidification of the incubation medium also affected the absolute  [3H]TC uptake 
and  [3H]preS1 binding rates (Fig. 4, bar graphs). Both functions of NTCP were significantly lower at pH of 5.5, 
most likely due to pH sensitive amino acid residues at the sites of substrate/preS1 binding.
Betulin derivatives inhibit HDV infection. Selected betulin derivatives were investigated for their 
inhibitory potency of in vitro HDV infection of NTCP-expressing HepG2 hepatoma cells. These experiments 
were of particular interest as in the  [3H]preS1 assays,  [3H]preS1 peptide binding is just used as a surrogate 
parameter for virus binding to NTCP. Of note, these infection experiments were performed in a different cell 
line as the screening assays and the betulin inhibitors had to be incubated much longer for the in vitro infection 
experiments (6 h) compared to the  [3H]preS1 binding assay (15 min). While NTCP-HepG2 cells without inhibi-
tor were used as control (set to 100% infection rate), co-incubation with 0.5 µM of the myr-preS12-48 lipopeptide 
completely abolished infection of the cells (set to 0% infection rate). As inhibitors for in vitro HDV infection, 
betulinic acid (4) was used as a potent but non-selective inhibitor, 20,29-dihydrobetulin (2) as a potent and 
highly selective inhibitor, as well as lupenone (17) and betulonoyl dimethyl-L-aspartate (19) as less potent but 
still selective inhibitors. All four compounds significantly blocked in vitro HDV infection of the NTCP-HepG2 
cells in a concentration-dependent manner (Fig. 5), clearly indicating that betulin derivatives represent an inter-
esting novel compound class of HBV/HDV entry inhibitors. Of note, none of the compounds induced toxicity in 
the cells even after long term incubation at high (300 µM/600 µM) inhibitor concentrations (Fig. 5h).
Inhibition of HDV infection cannot be attributed to drug‑induced internalization of 
NTCP. Compounds 4 and 17 underwent further investigations to clarify, whether their inhibitory effects on 
in vitro HDV infection may have been attributed to drug-induced internalization of NTCP. Therefore, NTCP-
expressing HepG2 hepatoma cells were pretreated with 600 µM of the respective compound for 15 min or 6 h, 
respectively (Fig. 5e,f). Subsequently, cells were washed three times with tempered PBS, before  [3H]TC (1 µM) 
uptake and  [3H]preS1 (5 nM) binding were analyzed for 10 min at 37 °C. Cells pretreated with solvent (DMEM) 
alone served as 100% controls. Data from HepG2 cells without NTCP expression were set to 0%. Even after three 
intense washing steps,  [3H]TC uptake was significantly reduced after short (15 min) and long (6 h) term pre-
incubation with compound 4. In contrast,  [3H]preS1 binding did not change, clearly confirming plasma mem-
brane localization of NTCP even after long term preincubation with high inhibitor concentrations of 600 µM. 
In the case of compound 17, no differences were observed after short term (15  min) preincubation, while 
[3H]TC uptake and  [3H]preS1 binding slightly changed in opposite directions after long term (6 h) preincuba-
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tion. These data confirm that also after preincubation with compound 17, NTCP remained at the plasma mem-
brane.
Discussion
The identification of the hepatic bile acid transporter NTCP as the high-affinity receptor for HBV and HDV was 
the basis for the development of a novel class of anti-HBV/anti-HDV drugs, being cell-entry inhibitors targeting 
 NTCP9. Since then, many studies have identified compounds that are capable to inhibit the virus receptor func-
tion of NTCP:  Hepcludex13, cyclosporine A and other cyclosporine  derivatives23–25,  ezetimibe10,  irbesartan27, 
 ritonavir28, (-)-epigallocatechin-3-gallate29, vanitaracin  A30, Ro41-525331,  proanthocyanidin32,  zafirlukast33, 
 sulfasalazine33, and Chicago Sky Blue 6B (an azo dye)33. Among them, Hepcludex is a peptide-based drug and 
cannot be administered  orally13. Furthermore, it has correspondingly complex manufacturing, storage, and 
distribution requirements. Therefore, it is still desirable to develop a small molecular drug with HBV/HDV 
cell-entry inhibitor activity that can be orally applied and would be easier to handle.
Many of the other mentioned compounds, e.g. cyclosporine A, were previously known to inhibit the bile acid 
transport function of  NTCP17. Others were identified as novel HBV/HDV inhibitors and later revealed their 
interference with the physiological bile acid transport function of NTCP. Overall, this interference indicates that 
NTCP domains relevant for substrate binding and transport overlap with the domains mediating myr-preS12-48 
lipopeptide / virus binding to NTCP. However, there are also some hints that both functions can be separated. 
In a previous study, we identified amino acid G158 of the human NTCP as absolutely essential for myr-preS12-48 
lipopeptide binding and in vitro HBV and HDV infection. This amino acid is located at a domain (amino acids 
157–165) that previously was shown to be involved in myr-preS12-48 binding to human  NTCP9,18. Accordingly, 
G158R NTCP mutants were completely insusceptible for in vitro HBV/HDV infection, but still supported trans-
port of bile acids. It was discussed that the larger amino acid side chain of arginine compared to glycine might 
sterically preclude myr-preS1 peptide binding, while bile acids can still bind to their respective binding  pocket34. 
Furthermore, Shimura et al.25 showed for the cyclosporine derivative SCY995 higher potency against in vitro 
HBV infection  (IC50 < 8 µM) than for bile acid transport inhibition  (IC50 > 25 µM).
Based on this, the present study was designed to enable the identification of a selective HBV/HDV cell-entry 
inhibitor from the group of small molecules. Therefore, all test compounds were a priori tested for both, inhibi-
tion of  [3H]preS1 binding to NTCP as a surrogate parameter for HBV/HDV infection and inhibition of  [3H]TC 
transport via NTCP. In the present study, a novel chemical class of promising HBV/HDV cell-entry inhibitors 
was identified, represented by derivatives of the natural pentacyclic lupane-type triterpenoid betulin. Betulin 
can be isolated from various plant species, belonging to a variety of families such as Betulaceae, Platanaceae, 
Dilleniaceae, Rhamnaceae, Rosaceae, and  Fagaceae35,36. Characteristics of the lupane skeleton of betulin are the 
five-membered E ring and the isopropylidene  group37. Interestingly, nearly all betulin derivatives tested in the 
present study significantly inhibited  [3H]TC transport and  [3H]preS1 binding. However, the ratios between the 
 IC50 values for transport inhibition and for  [3H]preS1 binding inhibition were quite different and the result-
ing selectivity indices ranged from 1 up to 65. The latter was the case for compound 2 with an  IC50 of 4 µM for 
 [3H]preS1 binding inhibition and an  IC50 of 260 µM for bile acid transport inhibition. Some other compounds 
showed no transport inhibition at all, being 24, 25, 28, and 30, but at least in the case of 25, potent inhibition of 
 [3H]preS1 peptide binding with  IC50 of 8 µM. This data clearly indicate structure–activity relationships for both 
NTCP functions. Of note, only small changes in the molecular structure of the betulin derivatives significantly 
changed their potency and selectivity index. Moreover, hydroxylation of compound 24 to compound 25, as an 
example, improved both factors in parallel: potency for  [3H]preS1 binding inhibition and the selectivity index. 
Also other modifications of the betulin molecule (1) such as 3-O-caffeoly conjugation (compound 27) or  C20-C30 
saturation (compound 2) significantly improved both factors simultaneously.
Inhibition studies at pH 5.5 revealed additional structure–activity relationships regarding the charge of the 
tested compounds. All potent but non-selective inhibitors (Fig. 3b) bear at least one acidic group at R1 and/or R2 
(see Tab. 1) and show pKa values between 4–5. Therefore, compounds from this group are predominantly depro-
tonated and negatively charged at physiological pH of 7.4, representing the standard condition in the inhibition 
assays. For comparison, also conjugated bile acids (pKa = 1–4) are predominantly deprotonated and negatively 
charged at physiological  pH38–40. Based on this it can be speculated that acidic betulin derivatives may not only be 
Figure 3.  Structure–activity relationships of betulin derivatives for  [3H]TC transport inhibition and  [3H]preS1 
binding inhibition. Chemical modifications at the lupane skeleton of betulin revealed clear structure–activity 
relationships for the potency (pot.,  IC50 of  [3H]preS1 binding inhibition) and virus selectivity index (sel. ind., 
ratio  IC50  [3H]TC transport inhibition /  IC50  [3H]preS1 binding inhibition). (a) 3,28-di-O-acetylation (shown 
in orange), additional  C29-hydroxylation (shown in purple), 3-O-modification with caffeoyl (shown in light-
blue), 28-oxime generation (shown in red), and  C30 saturation (shown in green) of the betulin core structure 
improve the potency and/or selectivity index of the respective compounds. The respective inhibition pattern 
are illustrated by bar graphs for  [3H]TC uptake (shown in dark-blue) and  [3H]preS1 peptide binding (shown in 
red), respectively, in the presence or absence of a fix concentration (100 µM) of the respective betulin derivative. 
Graphs show means ± SD of quadruplicate determinations. *Significantly different with p < 0.01 (two-way 
ANOVA with Sidak’s multiple comparison test); ns, not significant. (b) The diagram shows all  IC50 values for 
 [3H]TC uptake inhibition and  [3H]preS1 binding inhibition of the respective compounds. Effects  (IC50 shifts) 
of the structural modifications are illustrated by arrows, starting from the core structure betulin (compound 
1). Compounds can be divided into three groups regarding their potency to inhibit  [3H]preS1 binding: potent 
inhibitors  (IC50 ≤ 10 µM), less potent inhibitors (10 µM < IC50 < 100 µM) and poor inhibitors  (IC50 ≥ 100 µM). 
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inhibitors but also transporter substrates of NTCP. This would explain, why these compounds (representatively 
shown for compounds 4 and 8) largely lost their  [3H]TC uptake inhibitory potency when the pH was reduced 
to 5.5 and, thereby reducing the relative charge of the molecules. In contrast, the  [3H]preS1 binding inhibitory 
potency was insensitive to this pH shift and only showed little differences between pH 7.4 and pH 5.5 conditions. 
This again indicates that the transporter and the receptor function of NTCP can be separated under certain 
experimental conditions and that blocking of the preS1 peptide binding site of NTCP does not require negative 
charge of the inhibitor. In contrast to compounds 4 and 8, betulin itself (compound 1) does not bear any acidic 
group. Consequently, betulin could be less active at the bile acid binding site, what would explain the relatively 
low potency for TC uptake inhibition  (IC50 = 748 µM) at neutral and acidic pH values. However, no uniform 
legality could be established for the other chemical modifications of betulin, which would precisely predict the 
potency and selectivity pattern of the respective betulin derivative. Nevertheless, based on the structure–activ-
ity relationships described in the present study it is most likely that even more potent betulin derivatives can be 
identified, while sparing the cross-reactivity on the bile acid transport function of NTCP.
Among the betulin derivatives, betulinic acid (4) particularly underwent intensive toxicological 
 assessment35,41–43. In vitro and in vivo model systems consistently categorized betulinic acid (4) as a safe com-
pound with low toxicity. More precisely, no toxic effects were observed in rats that obtained single i.p. application 
of 400 mg/kg or in mice receiving 100 mg/kg i.p. every 3–4 days for a total of six treatments, or 500 mg/kg i.p. 
 once35,42,43. Unfortunately, betulinic acid (4), although potent in  [3H]preS1 binding inhibition  (IC50 = 2 µM), is not 
selective and showed equipotent inhibition of the bile acid transport function of NTCP at least at physiological 
pH. Therefore, betulinic acid (4) is not regarded as the optimal HBV/HDV entry inhibitor candidate from the 
betulin class of compounds. Apart from betulinic acid (4), betulin (1) also has a good safety profile. Betulin (1) 
is approved for medical use in humans and is currently available as a betulin containing gel (Oleogel-S10, Epis-
alvan). It was authorized in 2016 by the European Medicines Agency (EMA) for treatment of partial thickness 
wounds in adults. This gel contains an extract from birch bark of Betula pendula Roth, Betula pubescens Ehrh., 
and hybrids of both species, obtained with n-heptane as the extraction solvent. The resulting betulin (1) con-
centrations are in the range of 72–88 mg betulin (1) per 100 mg extract. The gel itself is composed of 10% birch 
bark extract in 90% sunflower oil. Moreover, Episalvan is currently undergoing a phase III efficacy and safety 
study in patients with inherited epidermolysis bullosa (EB) that started in 2017 with an estimated enrollment of 
250 participants (NCT03068780). Based on this good safety profile and the established use in human medicine, 
betulin (1) is an attractive early lead candidate for selective HBV/HDV cell-entry inhibition. However, despite its 
superior selectivity in comparison to betulinic acid (4), the potency for  [3H]preS1 binding inhibition is relatively 
Figure 4.  Influence of pH on the inhibition pattern of acidic betulin derivatives. NTCP-HEK293 cells 
were incubated with tetracycline in order to induce NTCP expression and were used for bile acid transport 
experiments with 1 µM  [3H]TC and for myr-preS12-48 lipopeptide binding experiments with 5 nM  [3H]preS1, 
each over 10 min at 37 °C. Cells without tetracycline treatment served as control (set to 0%). Experiments were 
performed with solvent alone (set to 100%) and with increasing concentrations of the indicated inhibitors in 
the range of 0.1 to 1,000 µM at pH 7.4 and pH 5.5, respectively. Diagrams show inhibition curves at pH 7.4 
(solid lines) and pH 5.5 (dashed lines). The mean of the 0% control was subtracted to calculate net  [3H]TC 
transport rates (shown in blue) as well as net  [3H]preS1 binding rates (shown in red), both expressed as % of 
control at the y-axis. Bar graphs show the relative  [3H]TC uptake rates (blue bars) and  [3H]preS1 binding rates 
(red bars) at pH 7.4 (filled bars) and pH 5.5 (striped bars), respectively, expressed as pmol/10 min/well. Half 
maximal inhibitory concentrations  (IC50) were calculated by nonlinear regression analysis using the equation 
log(inhibitor) vs. response (GraphPad Prism). Data represent means ± SD of quadruplicate determinations 
(n = 4). *Significantly different with p < 0.01 (unpaired t-test with Welch’s correction).
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low  (IC50 = 109 µM). Nevertheless, the present study clearly demonstrates that even small modifications of the 
lupane skeleton of betulin can improve the potency and selectivity of the respective compounds significantly. 
Therefore, it seems likely that advanced rational drug design can further improve this compound class to end 
up with a potent and selective HBV/HDV cell-entry inhibitor.
Apart from the above-mentioned clinical application, several previous studies showed that betulin (1) and 
betulin derivatives have a broad spectrum of pharmacological effects, including anti-cancer, anti-viral, anti-
microbial, anti-inflammatory, and anti-fibrotic  effects44–48. Interestingly, betulinic acid (4) was also used in HBV 
infection studies before, which showed inhibition of HBV replication by suppression of manganese superoxide 
dismutase (SOD2) expression with subsequent mitochondrial reactive oxygen species (ROS) over-generation49. 
Based on this and the results from the present study, betulinic acid (4) might have additive HBV/HDV antiviral 
properties by addressing different cellular targets involved in cell-entry (NTCP) and replication (SOD2). There-
fore, further studies with betulin derivatives should take selective NTCP inhibition and potential suppression 
of SOD2 into account, which was beyond the scope of the present study.
Our  [3H]preS1 binding assay successfully predicted the inhibitory effect of the betulin derivatives on in vitro 
HDV infection. A minor but expected limitation is that absolute  IC50 values varied between both experimental 
setups. While the qualitative activity pattern of the betulin derivatives remained the same between the two assays, 
the absolute  IC50 values for in vitro HDV infection inhibition were about one to two orders of magnitude higher 
than predicted from the  [3H]preS1 binding experiments. Most likely, several factors contribute to this effect. 
One factor could be the different incubation times for  [3H]preS1 binding (minutes) and in vitro HDV infection 
experiments (hours). Another factor might be the use of different cell lines and incubation media. Whereas, the 
 [3H]preS1 binding assays were performed in NTCP-HEK293 cells in pure DMEM, the infection experiments 
needed to be performed with NTCP-HepG2 cells in HGM containing significant amounts of bovine serum 
albumin (BSA) as well as polyethylene glycol (PEG). The latter medium conditions potentially alter free drug 
concentrations due to protein binding. Lowering of the inhibitory potency of betulinic acid (4) due to protein 
binding has already been identified in a previous study, where this compound was used as inhibitor for the 
organic anion transporting polypeptide  OATP1B350. A further factor could be the different stoichiometry of the 
single preS1 peptide molecule and the multitude of preS1 domains of the large envelope proteins of HBV/HDV 
virions. The latter one could need a higher degree of blocked NTCP receptors for successful virus binding and 
cell-entry inhibition. On this background, it could be beneficial if an NTCP inhibitor would not only be selective, 
but would also irreversibly block the preS1/virus binding sites at NTCP. However, this was not achieved with 
the betulin derivatives analyzed in the present study. The data obtained on compounds 4 and 17 more suggest a 
reversible mode of inhibition for myr-preS12-48 peptide binding to NTCP. Their inhibitory effect on  [3H]preS1 
binding was completely abrogated by washing the cell surface with inhibitor-free medium (see Fig. 5e,f). But, 
these observations clearly indicate that the inhibitory effects of compounds 4 and 17 on HDV infection cannot 
be attributed to drug-induced internalization of NTCP.
Of interest are also the long-term effects of compounds 4 and 17 on the transporter and receptor function of 
NTCP. In the case of compound 4 preincubation with 600 µM significantly and selectively reduced the transporter 
function of NTCP, while NTCP still was completely preS1 peptide binding competent. As compound 4 (betulinic 
acid) belongs to the group of acidic betulin derivatives one can speculate that betulinic acid is transported by 
NTCP, accumulates inside the cell during preincubation and so by trans-inhibiton blocks substrate binding but 
not preS1 peptide binding to the outer surface of the NTCP protein. This again would support the idea that bile 
acid and preS1 peptide binding to NTCP occur at separate, but overlapping domains. In contrast, compound 17 
showed a paradoxical effect after long term preincubation and increased the capacity for  [3H]preS1 peptide bind-
ing to approximately 130%, while the  [3H]TC uptake rate was slightly reduced. This could be explained by longer 
lasting allosteric effects of this compound that differently affects the transport and receptor function of NTCP. 
The mechanism behind these effects could not be clarified in the present study and needs further investigation, 
including LC–MS/MS supported direct transport experiments with key betulin derivatives.
In conclusion, betulin derivatives show clear structure–activity relationships for potent and selective inhibi-
tion of the HBV/HDV virus receptor function of NTCP without tackling its physiological bile acid transport 
function. Therefore, betulin derivatives are promising candidates for further development of HBV/HDV cell-
entry inhibitors. Further studies with this compound class should additionally focus on the mode of inhibition 
(reversible vs. irreversible) and should be extended to all relevant HBV genotypes.
Methods
NTCP‑expressing cell lines. Human embryonic kidney (HEK293) cells were stably transfected with 
human NTCP, C-terminally tagged with the FLAG epitope (further referred to as NTCP-HEK293 cells) as 
reported  before51. Cells were maintained at 37 °C, 5%  CO2 and 95% humidity in DMEM/F-12 medium (Thermo 
Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO, 
USA), 4 mM L-glutamine (PAA, Cölbe, Germany) and penicillin/streptomycin (PAA). HepG2 cells stably trans-
fected with NTCP-FLAG (further referred to as NTCP-HepG210) were cultured under the same conditions in 
DMEM with all supplements listed above, except for L-glutamine. For induction of the transgene, the medium 
was supplemented with 1 µg/ml tetracycline (Roth, Karlsruhe, Germany) in the case of the NTCP-HEK293 cells 
or with 2 µg/ml doxycycline (Sigma-Aldrich) in the case of the NTCP-HepG2 cells.
Inhibitory concentrations  (IC50) for  [3H]preS1 binding and  [3H]TC transport. Bile acid transport 
measurements were performed in the NTCP-HEK293 cells with  [3H]TC (20  Ci/mmol, 0.09  mCi/ml, Perkin 
Elmer, Waltham, USA) as reported  before51. In parallel,  [3H]preS1 peptide binding experiments were performed 
with a tritium-labelled myr-preS12-48 lipopeptide -HBV subgenotype D3- that was purchased from Pharmaron 
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(120 Ci/mmol, 1 mCi/ml, Cardiff, UK). Briefly, cells were seeded onto polylysine-coated 96-well plates, induced 
with 1 µg tetracycline per ml, and grown to confluence over 72 h at 37 °C. Then, cells were washed once with 
tempered phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 7.3 mM Na2HPO4, 
pH 7.4) at 37 °C and preincubated with 80 µl DMEM for 5 min at 37 °C. The medium was replaced by 80 µl 
DMEM containing the respective betulin derivative (concentrations ranging from 0.1 to 1,000 µM) or solvent 
alone (100% uptake/binding control), and cells were further incubated for 5 min at 37 °C. After this preincuba-
tion, bile acid transport experiments were started by adding 20 µl DMEM containing 5 µM  [3H]TC (final con-
centration: 1 µM). Binding of  [3H]preS1 was initiated by adding 20 µl DMEM containing 25 nM  [3H]preS1 (final 
concentration: 5 nM). Experiments were stopped after 10 min by two-times washing with ice-cold PBS. For 
0% uptake/binding control, the NTCP-HEK293 cells were not induced with tetracycline (-tet). Cell-associated 
radioactivity of  [3H]TC or  [3H]preS1 was quantified by liquid scintillation counting in a Packard Microplate 
Scintillation Counter TopCount NXT (Packard Instrument Company, Meriden, USA). Transport rates and  [3H]
preS1 binding were determined in counts per minute (cpm). The mean of the 0% control was subtracted and 
the net  [3H]TC transport rates and net  [3H]preS1 binding rates, respectively, were expressed as % of control. 
Experiments at pH 5.5 were performed the same way, using DMEM acidified with hydrochloric acid (32%, 
Roth). A set of betulin derivatives was purchased from Adipogen AG (Liestal, Switzerland), including the com-
pounds betulin (1), betulinic acid (4), lupeol (3), betulonaldehyde (18), lupenone (17), 3-O-caffeoylbetulin (27), 
3,28-di-O-acetylbetulin (24), 28-O-(3,3-dimethylglutaroyl)betulin (10), 3,28-di-O-(3,3-dimethylglutaroyl)bet-
ulin (12), 28-O-succinoylbetulin (8), 3,28-di-O-succinoylbetulin (9), 3-O-(3,3-dimethylglutaroyl)betulinic acid 
(11), and 3-O-acetylbetulinic acid (21) (TargoSet). All other betulin derivatives were synthesized as outlined 
 elsewhere52–54.  IC50 values were calculated from quadruplicate determinations by GraphPad Prism 6 (GraphPad, 
San Diego, CA, USA).
HDV infection experiments. For infection experiments NTCP-HepG2 cells were cultured in 96-well 
plates in Hepatocyte Growth Medium (HGM) consisting of William’s E Medium (Thermo Fisher Scientific) con-
taining 2% bovine serum albumin (BSA, Roth), 2 mM L-Glutamin (Thermo Fisher Scientific), 100 µg/ml gen-
tamicin (Thermo Fisher Scientific), 10 nM dexamethasone (Sigma-Aldrich), 1 mM sodium pyruvate (Thermo 
Fisher Scientific), 1 × Insulin-Transferrin-Selen (Thermo Fisher Scientific), 2% DMSO (Merck, Darmstadt, Ger-
many), 4% polyethylene glycol (Sigma-Aldrich) and 2 µg/ml doxycycline (Sigma-Aldrich) as  reported10. Sub-
sequently, cells were washed with DMEM and cultured in HGM supplemented with 2% DMSO, 2% BSA and 
2 µg/ml doxycycline. NTCP-HepG2 cells were preincubated for 5 min with inhibitors solved in 80 µl HGM per 
well in concentrations ranging from 5 µM to 300 µM (compounds 2 and 19) or from 5 µM to 600 µM (com-
pounds 4 and 17). HDV stock solved in 20 µl HGM per well was added for infection and cells were incubated 
for 6 h with final concentration of 700 genome equivalents/cell of HDV particles. HDV production was done 
in vitro as described  before55,56. RT-qPCR was performed to determine genome equivalents. Every three days 
medium was changed until cells were fixed at 9 days post infection with 3% paraformaldehyde (Sigma-Aldrich) 
in PBS, for 30 min at room temperature (RT). Cells were permeabilized with 0.2% Triton X 100 (Roth) in PBS for 
30 min at RT, and blocked by incubation with 5% bovine serum albumin (Roth) in PBS, for 30 min at RT. Then, 
cells were immunostained with purified human anti-HDV-positive serum at 37 °C for 1 h (1:400 dilution). Goat 
anti-human IgG secondary antibody coupled to Alexa Fluor fluorophore (1:400 dilution, Thermo Fisher Scien-
tific) was added for 1 h at 37 °C for detection of Hepatitis Delta antigen (HDAg) as described  before34. Nuclei 
were stained with Hoechst 33342 (1 µg/ml, Thermo Fisher Scientific).
Preincubation studies in NTCP‑HepG2 cells. NTCP-expressing HepG2 hepatoma cells were seeded 
onto rat tail collagen coated 24-well plates, induced with 2 µg doxycycline per ml, and grown to confluence over 
72 h at 37 °C. For experiments, cells were preincubated with a fix concentration (600 µM) of compound 4 and 
Figure 5.  Selected betulin derivatives were used for HDV infection inhibition of NTCP-HepG2 cells. NTCP-
HepG2 cells were preincubated for 5 min with the indicated concentrations of (a) betulinic acid (compound 4), 
(b) lupenone (compound 17), (c) betulonoyl dimethyl-L-aspartate (compound 19), (d) 20,29-dihydrobetulin 
(compound 2), and (g) the myr-preS12-48 peptide in DMEM at 37 °C. Then, cells were additionally inoculated 
with 700 genome equivalents/cell of HDV particles at 37 °C. After 6 h, cells were washed and further incubated 
with inhibitor- and virus-free medium, and medium was changed every 3–4 days. At day 9 post infection, 
cells were fixed and an immunostaining against the HDAg was performed, as a marker of HDV infection. The 
number of infected cells per well was determined by fluorescence microscopy. NTCP-HepG2 cells incubated 
without inhibitor were used as control (set to 100% infection rate). Infection experiments in the presence of 
0.5 µM myr-preS12-48 peptide served as control for the 0% infection rate. Scale bars: 100 µm. Data represent 
means ± SEM of three independent experiments each with triplicate determinations (n = 9). (e, f) Cells were 
preincubated with 600 µM of compound 4 and compound 17, respectively, for intervals of 15 min and 6 h at 
37 °C. Cells treated with solvent (DMEM) alone served as control (set to 100%) and data from cells without 
induction of NTCP expression were set to 0%. Subsequently, cells were washed three times with tempered 
PBS and  [3H]TC (1 µM) uptake as well as  [3H]preS1 (5 nM) binding were analyzed, respectively. Means of the 
0% controls were subtracted and net  [3H]TC transport rates and net  [3H]preS1 binding rates are expressed as 
% of control at the y-axis. Data were combined from two independent experiments, each with quadruplicate 
determinations (n = 8). (h) Cell viability was determined with an LDH cytotoxicity assay. HepG2 cells treated 
with HGM w/o test compound were used as positive control and lysed cells as negative control. Data show 
means ± SD of three independent experiments each with triplicate determinations (n = 9). *Significantly different 
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compound 17, respectively, solved in 300 µl DMEM for intervals of 15 min or 6 h at 37 °C. Cells treated with 
solvent alone (DMEM) were used as 100% controls. Cells without induction of NTCP expression by doxycycline 
were used as 0% controls. Subsequently, cells were washed three times with tempered PBS. Then,  [3H]TC uptake 
and  [3H]preS1 binding experiments were started by adding 300 µl of 1 µM  [3H]TC or 5 nM  [3H]preS1, respec-
tively. After 10 min, experiments were stopped by washing the cells 5 times with ice-cold PBS. Cell-associated 
radioactivity was quantified by liquid scintillation counting as described above.  [3H]TC uptake and  [3H]preS1 
binding rates were determined in pmol/mg protein/10 min. Means of the 0% controls were subtracted and the 
net  [3H]TC uptake and net  [3H]preS1 binding rates, respectively, were expressed as % of control. Data were 
calculated from two independent experiments, each with quadruplicate determinations by GraphPad Prism 6 
(GraphPad, San Diego, CA, USA).
Cytotoxicity assay. Pierce lactate dehydrogenase (LDH) cytotoxicity assay (Thermo Fisher Scientific) was 
performed according to the manufacturer’s protocol. Briefly, NTCP-HepG2 cells were incubated with 300 µM or 
600 µM of the respective betulin derivatives over 6 h at 37 °C. 45 min before the end of incubation, lysis buffer 
was added to the maximal LDH control. After 6 h, 50 µl of each sample and control medium were transferred to 
a new well plate, 50 µl of the reaction mixture were added and incubation was performed over 30 min at room 
temperature. Finally, the reaction was stopped by adding 50 µl of stop solution and samples were measured by 
ELISA reader (GloMax-Multi Detection System, Promega, Madison, WI, USA).
Structure modeling and pKa determination. 2D compound structures were generated using the 
MAESTRO 12.2 Molecular Modeling Interface of SCHRÖDINGER, Inc. (New York City, NY, USA). The Jaguar 
pKa prediction module of the SCHRÖDINGER software was used to calculate pKa values of compounds 4 and 
8.
Statistics. Determination of  IC50 values was done by nonlinear regression analysis using the equation 
log(inhibitor) vs. response settings of the GraphPad Prism 6.0 software (GraphPad). Data of bile acid transport 
and  [3H]preS1 binding are expressed as means ± SD from quadruplicate determinations.  IC50 values are listed 
with their 95% confidence intervals in Table 2. In addition, mean  IC50 values were calculated for each experi-
ment. Infection studies show data from three independent experiments, each with triplicate determinations rep-
resented as means ± SEM. Statistical analyses of the HDV infection experiments and NTCP-HepG2 preincuba-
tion studies were performed by two-way ANOVA, followed by Dunnett’s multiple comparison test by GraphPad 
Prism 6.0, considering p < 0.01 as statistically significant.
Data availability
Obtained and analyzed data of this study are available from the corresponding author on request.
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